Skip to main content
Figure 2 | Pediatric Rheumatology

Figure 2

From: Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis

Figure 2

Improved and normal visual acuity on Adalimumab. a-b. Number of children (a) as well the number of eyes (b) with improved (black bar) and not improved (white bar) visual acuity at 1 year of treatment in Group 1, receiving Adalimumab as first anti-TNFα therapy, and Group 2, receiving Adalimumab as second anti-TNFα therapy. (χ2: 11.5, p < 0.001; and χ2: 12.7, p < 0.001, respectively). c-d. Number of children (c) as well number of eyes (d) with normal (black bar) and abnormal (white bar) visual acuity at 1 year of treatment in Group 1, receiving Adalimumab as first anti-TNFα therapy, and in Group 2, receiving Adalimumab as second anti-TNFα therapy (χ2: 4.9, p < 0.04; and χ2: 6.4, p < 0.02, respectively).

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096